Back to Journals » Cancer Management and Research » Volume 5

Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management

Authors Mason JW, Moon TE

Received 3 March 2013

Accepted for publication 29 April 2013

Published 29 July 2013 Volume 2013:5 Pages 179—185

DOI https://doi.org/10.2147/CMAR.S34352

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 6


Jay W Mason,1 Thomas E Moon2

1School of Medicine, University of Utah, Salt Lake City, UT, 2Tarizona eHealth Services, Inc, Emeryville, CA, USA

Abstract: 5-HT3 antagonists have been available as oral and intravenous preparations for decades. The availability more recently of transdermal granisetron and the anticipated availability of a subcutaneous granisetron preparation have provided helpful alternatives to patients, and these preparations have been shown to have less potential to prolong QT than other drugs in the class.

Keywords: chemotherapy-induced nausea, vomiting, granisetron, QT prolongation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]